Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/77314
DC Field | Value | Language |
---|---|---|
dc.contributor.author | del Amo, Julia | en_US |
dc.contributor.author | Polo, Rosa | en_US |
dc.contributor.author | Moreno, Santiago | en_US |
dc.contributor.author | Díaz, Asunción | en_US |
dc.contributor.author | Martínez, Esteban | en_US |
dc.contributor.author | Arribas, José Ramón | en_US |
dc.contributor.author | Jarrín, Inma | en_US |
dc.contributor.author | Hernán, Miguel A. | en_US |
dc.contributor.author | Pérez Arellano, José Luis | en_US |
dc.date.accessioned | 2021-01-25T15:03:48Z | - |
dc.date.available | 2021-01-25T15:03:48Z | - |
dc.date.issued | 2020 | en_US |
dc.identifier.issn | 0003-4819 | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/77314 | - |
dc.description.abstract | Background: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations. Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. Participants: 77 590 HIV-positive persons receiving ART. Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction–confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. Limitation: Residual confounding by comorbid conditions cannot be completely excluded. Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. Primary Funding Source: Instituto de Salud Carlos III and National Institutes of Health. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Annals of internal medicine | en_US |
dc.source | Annals of internal medicine [ISSN 0003-4819], v. 173 (7) | en_US |
dc.subject | 3202 Epidemologia | en_US |
dc.title | Incidence and severity of COVID-19 in HIV-Positive persons receiving antiretroviral therapy | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.7326/M20-3689 | en_US |
dc.identifier.issue | 7 | - |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.utils.revision | Sí | en_US |
dc.identifier.ulpgc | No | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.sjr | 3,839 | |
dc.description.jcr | 25,391 | |
dc.description.sjrq | Q1 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | GIR IUIBS: Trypanosomosis, Resistencia a Antibióticos y Medicina Animal | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-2936-8242 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Pérez Arellano, José Luis | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.